ACADIA PHARMACEUTICALS INC

ACADUnited States

92 filed reports · 487 financial concepts · 12 earnings calls

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$1.07B

FY2025 · to Dec 31, 2025

up +11.9% vs $958M

10-K

Net income

$391M

FY2025 · to Dec 31, 2025

up +72.7% vs $226M

10-K

Operating income

$105M

FY2025 · to Dec 31, 2025

down −54.6% vs $231M

10-K

Latest quarter

Revenue

$342M

Q3 FY2026 · to Sep 30, 2026

up +22.8% vs $279M

10-Q

Net income

$53.5M

Q3 FY2026 · to Sep 30, 2026

down −25.4% vs $71.8M

10-Q

Operating income

$71.7M

Q3 FY2026 · to Sep 30, 2026

up +101% vs $35.8M

10-Q

Filed reports

92 reports · Jun 2011 to Sep 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 63 guidance figures, 58 earnings-release figures, 28 commentary passages.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR475,229Jun 2011 to Sep 2026
Current · 8-KSEC EDGAR3088Dec 2012 to Sep 2026
Annual · 10-KSEC EDGAR155,127Dec 2011 to Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q310-Q2026-09-302026-11-05343Open
FY2026 Q38-K2026-09-302026-11-0425Open
FY2026 Q210-Q2026-06-302026-08-05211Open
FY2026 Q28-K2026-06-302026-08-042Open
FY2026 Q110-Q2026-03-312026-05-07216Open
FY2026 Q18-K2026-03-312026-05-062Open
FY202510-K2025-12-312026-02-26774Open
FY2025 Q48-K2025-12-312026-02-252Open
FY2025 Q48-K2025-12-312026-01-131Open
FY2025 Q310-Q2025-09-302025-11-06153Open
FY2025 Q38-K2025-09-302025-11-052Open
FY2025 Q210-Q2025-06-302025-08-07152Open

Financial data

487 concepts · 10,444 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial467 concepts · 10,186 facts · Dec 2009 to Sep 2026

  • Cash and cash equivalents at carrying value84 · Dec 2009 to Sep 2026
  • Net income loss84 · Dec 2009 to Sep 2026
  • Operating income loss84 · Dec 2009 to Sep 2026
  • Research and development expense84 · Dec 2009 to Sep 2026
  • Revenue84 · Dec 2009 to Sep 2026
  • Depreciation82 · Dec 2009 to Sep 2026
  • Increase decrease in accounts payable82 · Dec 2009 to Sep 2026
  • Increase decrease in accrued liabilities82 · Dec 2009 to Sep 2026
  • Proceeds from issuance of common stock82 · Dec 2009 to Sep 2026
  • Stockholders equity (US GAAP)81 · Dec 2009 to Sep 2026
  • Share based compensation80 · Dec 2009 to Sep 2026
  • Accounts payable current79 · Dec 2010 to Sep 2026
  • Accretion amortization of discounts and premiums investments79 · Dec 2010 to Sep 2026
  • Accrued liabilities current79 · Dec 2010 to Sep 2026
  • Assets79 · Dec 2010 to Sep 2026
  • Assets current79 · Dec 2010 to Sep 2026
  • Common stock par or stated value per share79 · Dec 2010 to Sep 2026
  • Common stock shares authorized79 · Dec 2010 to Sep 2026
  • Common stock shares issued79 · Dec 2010 to Sep 2026
  • Common stock shares outstanding79 · Dec 2010 to Sep 2026
  • Common stock value79 · Dec 2010 to Sep 2026
  • Comprehensive income net of tax79 · Dec 2010 to Sep 2026
  • Liabilities and stockholders equity79 · Dec 2010 to Sep 2026
  • Liabilities current79 · Dec 2010 to Sep 2026

Segment10 concepts · 160 facts · Dec 2022 to Sep 2026

  • Revenue42 · Dec 2022 to Jun 2026
  • Cost of goods and services sold (US GAAP)15 · Dec 2022 to Sep 2026
  • Royalty expense15 · Dec 2022 to Sep 2026
  • Income tax expense benefit14 · Dec 2022 to Jun 2026
  • Interest income expense nonoperating net14 · Dec 2022 to Jun 2026
  • Net income loss14 · Dec 2022 to Jun 2026
  • Other nonoperating income expense14 · Dec 2022 to Jun 2026
  • Research and development expense14 · Dec 2022 to Jun 2026
  • Selling general and administrative expense14 · Dec 2022 to Jun 2026
  • Gain loss on sale of other assets4 · Dec 2022 to Dec 2025

Guidance2 concepts · 65 facts · Mar 2013 to Nov 2026

  • Revenue Guidance61 · Aug 2017 to Nov 2026
  • Free Cash Flow Guidance4 · Mar 2013 to May 2013

KPI6 concepts · 22 facts · Sep 2025 to Sep 2026

  • Cost of product sales4 · Sep 2025 to Sep 2026
  • Product sales, net4 · Sep 2025 to Sep 2026
  • Research and development4 · Sep 2025 to Sep 2026
  • Selling, general and administrative4 · Sep 2025 to Sep 2026
  • Total revenues4 · Sep 2025 to Sep 2026
  • Cash, cash equivalents and investment securities2 · Dec 2025 to Sep 2026

Product2 concepts · 11 facts · Dec 2016 to Sep 2026

  • Revenue8 · Dec 2016 to Sep 2026
  • Cost of goods and services sold (US GAAP)3 · Dec 2016 to Dec 2018

Segments

171 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments1 member · 160 facts

  • Reportable Segment Aggregation Before Other Operating160 · Dec 2022 to Sep 2026

Product or service4 members · 11 facts

  • Product6 · Dec 2016 to Dec 2018
  • Daybue2 · Sep 2025 to Sep 2026
  • Nuplazid2 · Sep 2025 to Sep 2026
  • Product And Service Other1 · Dec 2016

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

  • Earnings-release commentary10 claims from 1 report · Sep 2026
  • Management discussion (MD&A) commentary18 claims from 1 report · Sep 2026
  • Risk-factor changes229 claims from 13 reports · Dec 2012 to Dec 2024
  • Risk factors676 risks from 14 annual reports · 2011 to 2024

Earnings calls

12 calls · Feb 2024 to Nov 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q32026-11-04
  • FY2026 Q22026-08-04
  • FY2026 Q12026-05-06
  • FY2025 Q42026-02-26
  • FY2025 Q32025-11-06
  • FY2025 Q22025-08-07
  • FY2025 Q12025-05-07
  • FY2024 Q42025-02-26
  • FY2024 Q32024-11-06
  • FY2024 Q22024-08-06
  • FY2024 Q12024-05-08
  • FY2023 Q42024-02-27

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of ACADIA PHARMACEUTICALS INC (ACAD) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.

ACADIA PHARMACEUTICALS INC (ACAD): FY2025 revenue $1.07B · FactIQ